ChromaDex (NASDAQ:CDXC - Get Free Report) will issue its quarterly earnings data after the market closes on Wednesday, May 8th. Analysts expect the company to announce earnings of ($0.03) per share for the quarter. Parties that are interested in participating in the company's conference call can do so using this link.
ChromaDex Price Performance
Shares of CDXC stock traded up $0.12 on Wednesday, hitting $3.66. The stock had a trading volume of 140,869 shares, compared to its average volume of 257,939. The firm has a market capitalization of $276.40 million, a P/E ratio of -52.28 and a beta of 1.99. ChromaDex has a 1 year low of $1.25 and a 1 year high of $4.65. The company's 50 day moving average price is $3.00 and its 200-day moving average price is $1.99.
Analyst Ratings Changes
CDXC has been the topic of several research analyst reports. StockNews.com assumed coverage on ChromaDex in a report on Sunday, March 3rd. They issued a "strong-buy" rating on the stock. Roth Mkm boosted their target price on ChromaDex from $4.25 to $6.00 and gave the stock a "buy" rating in a research note on Tuesday, April 9th.
Get Our Latest Report on CDXC
ChromaDex Company Profile
(
Get Free Report)
ChromaDex Corporation operates as a bioscience company focusing on developing healthy aging products. The company operates through three segments: Consumer products; Ingredients; and Analytical Reference Standards and Services. It researches nicotinamide adenine dinucleotide (NAD+); provides finished dietary supplement products that contain its proprietary ingredients directly to consumers and distributors; and develops and commercializes proprietary-based ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products.
See Also
Before you consider ChromaDex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and ChromaDex wasn't on the list.
While ChromaDex currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.
Get This Free Report
